Data form TARA trial Taper in RA remission Flare free survival at 2 yrs 35% Risk of flare is similar in ACPA+ & ACPA- RA Risk of flare is similar if taper TNFi first or csDMARD first @RheumNow #EULAR2024 POS0405 https://t.co/89gAglHUcw